Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease

被引:21
作者
Barrett, M. J. [1 ]
Hagenah, J. [2 ]
Dhawan, V. [3 ]
Peng, S. [3 ]
Stanley, K. [1 ]
Raymond, D. [1 ]
Deik, A. [1 ]
Gross, S. J. [4 ,5 ]
Schreiber-Agus, N. [5 ]
Mirelman, A. [6 ,7 ]
Marder, K. [8 ]
Ozelius, L. J. [9 ]
Eidelberg, D. [3 ]
Bressman, S. B. [1 ,10 ]
Saunders-Pullman, R. [1 ,10 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA
[2] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany
[3] Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY 11030 USA
[4] Albert Einstein Coll Med, Dept Obstet & Gynecol, North Bronx Healthcare Network, Bronx, NY 10467 USA
[5] North Bronx Healthcare Network, Jacobi Med Ctr, Human Genet Lab, Bronx, NY USA
[6] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, IL-69978 Tel Aviv, Israel
[7] Ben Gurion Univ Negev, Beer Sheva, Israel
[8] Columbia Univ, Med Ctr, New York, NY 10027 USA
[9] Mt Sinai Sch Med, Dept Genet, New York, NY 10029 USA
[10] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA
关键词
Parkinson disease; Parkinsonism; Diffuse Lewy body disease; Transcranial sonography; PET; Glucocerebrosidase; GBA; Gaucher disease; LRRK2; GAUCHER-DISEASE; NETWORK MODULATION; SUBSTANTIA-NIGRA; GBA MUTATIONS; SUSCEPTIBILITY; PHENOTYPE; CARRIERS; G2019S; ONSET; LRRK2;
D O I
10.1016/j.parkreldis.2012.09.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Heterozygous glucocerebrosidase (GBA) mutations are the leading genetic risk factor for Parkinson disease, yet imaging correlates, particularly transcranial sonography, have not been extensively described. Methods: To determine whether GBA mutation heterozygotes with Parkinson disease demonstrate hyperechogenicity of the substantia nigra, transcranial sonography was performed in Ashkenazi Jewish Parkinson disease subjects, tested for the eight most common Gaucher disease mutations and the LRRK2 G2019S mutation, and in controls. [F-18]-fluorodeoxyglucose or [F-18]-fluorodopa positron emission tomography is also reported from a subset of Parkinson disease subjects with heterozygous GBA mutations. Results: Parkinson disease subjects with heterozygous GBA mutations (n = 23) had a greater median maximal area of substantia nigral echogenicity compared to controls (n = 34, aSNmax = 0.30 vs. 0.18, p = 0.007). There was no difference in median maximal area of nigral echogenicity between Parkinson disease groups defined by GBA and LRRK2 genotype: GBA heterozygotes; GBA homozygotes/compound heterozygotes (n = 4, aSNmax = 0.27); subjects without LRRK2 or GBA mutations (n = 32, aSNmax = 0.27); LRRK2 heterozygotes/homozygotes without GBA mutations (n = 27, aSNmax = 0.28); and GBA heterozygotes/LRRK2 heterozygotes (n = 4, aSNmax = 0.32, overall p = 0.63). In secondary analyses among Parkinson disease subjects with GBA mutations, maximal area of nigral echogenicity did not differ based on GBA mutation severity or mutation number. [F-18]-fluorodeoxyglucose (n = 3) and [F-18]-fluorodopa (n = 2) positron emission tomography in Parkinson disease subjects with heterozygous GBA mutations was consistent with findings in idiopathic Parkinson disease. Conclusions: Both transcranial sonography and positron emission tomography are abnormal in GBA mutation associated Parkinson disease, similar to other Parkinson disease subjects. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 41 条
[1]   The metabolic pathology of dopa-responsive dystonia [J].
Asanuma, K ;
Ma, YL ;
Huang, CR ;
Carbon-Correll, M ;
Edwards, C ;
Raymond, D ;
Bressman, SB ;
Moeller, JR ;
Eidelberg, D .
ANNALS OF NEUROLOGY, 2005, 57 (04) :596-600
[2]   Network modulation in the treatment of Parkinson's disease [J].
Asanuma, Kotaro ;
Tang, Chengke ;
Ma, Yilong ;
Dhawan, Vijay ;
Mattis, Paul ;
Edwards, Christine ;
Kaplitt, Michael G. ;
Feigin, Andrew ;
Eidelberg, David .
BRAIN, 2006, 129 :2667-2678
[3]   Gaucher's disease with Parkinson's disease - Clinical and pathological aspects [J].
Bembi, B ;
Marsala, SZ ;
Sidransky, E ;
Ciana, G ;
Carrozzi, M ;
Zorzon, M ;
Martini, C ;
Gioulis, M ;
Pittis, MG ;
Capus, L .
NEUROLOGY, 2003, 61 (01) :99-101
[4]   Microglia activation is related to substantia nigra echogenicity [J].
Berg, D. ;
Godau, J. ;
Riederer, P. ;
Gerlach, M. ;
Arzberger, T. .
JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (11) :1287-1292
[5]   Echogenicity of the substantia nigra in Parkinsons disease and its relation to clinical findings [J].
Berg, D ;
Siefker, C ;
Becker, G .
JOURNAL OF NEUROLOGY, 2001, 248 (08) :684-689
[6]   Hematologically important mutations: Gaucher disease [J].
Beutler, E ;
Gelbart, T ;
Scott, CR .
BLOOD CELLS MOLECULES AND DISEASES, 2005, 35 (03) :355-364
[7]   Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal [J].
Bras, Jose ;
Paisan-Ruiz, Coro ;
Guerreiro, Rita ;
Ribeiro, Maria Helena ;
Morgadinho, Ana ;
Januario, Cristina ;
Sidransky, Ellen ;
Oliveira, Catarina ;
Singleton, Andrew .
NEUROBIOLOGY OF AGING, 2009, 30 (09) :1515-1517
[8]   GBA-associated PD presents with nonmotor characteristics [J].
Brockmann, K. ;
Srulijes, K. ;
Hauser, A. -K. ;
Schulte, C. ;
Csoti, I. ;
Gasser, T. ;
Berg, D. .
NEUROLOGY, 2011, 77 (03) :276-280
[9]  
Brueggemann N, 2008, NEUROLOGY, V71, P1294, DOI 10.1212/01.wnl.0000338439.00992.c7
[10]   Substantia Nigra Hyperechogenicity with LRRK2 G2019S Mutations [J].
Brueggemann, Norbert ;
Hagenah, Johann ;
Stanley, Kaili ;
Klein, Christine ;
Wang, Cuiling ;
Raymond, Deborah ;
Ozelius, Laurie ;
Bressman, Susan ;
Saunders-Pullman, Rachel .
MOVEMENT DISORDERS, 2011, 26 (05) :885-888